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but requires some attempts. Transesophageal
echocardiography confirmed right pump
placement and no interference between
valve leaflet movements and outflow-tip
antegrade flow. A trivial aortic regurgita-
tion was detected, probably because of the
relative stiffness of prosthetic compared
with natural valve leaflets. The postopera-
tive course was characterized by persistent
oliguria that required central veno–venous
haemofiltration, with slow improvement of
cardiac function. Inotropic support was
continued for 6 days and then slowly de-
creased. After 15 days of support, the pa-
tient was weaned from the device and
discharged home. Follow-up echocardi-
ography showed markedly improved left
ventricular contractility and good perfor-
mance of the aortic valve without signs of
damage to the leaflets.4
We agree with the author that in the set-
ting of postcardiotomy heart failure, deciding
when to start a patient on mechanical support
without wasting any precious time is the key
to success. Recently, we have introduced in
our clinical practice the IABP score as a
very useful tool in the decision-making
process of mechanical support in postcar-
diotomy heart failure. Hausmann and col-
leagues3 defined an IABP score based on 4
parameters they found statistically signifi-
cant to predict survival or death 1 hour
after IABP implantation in patients with
low-output syndrome in cardiac surgery.
The Hausmann IABP score has been vali-
dated also by Siegenthaler and associates5
in their study of 24 patients supported with
the Impella LD for postcardiotomy heart
failure. In addition, they were able to iden-
tify patients who will not benefit from the
Impella Recover. Patients with a residual
cardiac function of 1 L/min or less had an
88% chance of death. This observation is
likely due to the fact that the Impella de-
vice provides insufficient support in the
presence of virtually absent myocardial
function.
In conclusion, we agree with the au-
thors that timely insertion of such a device
in the postcardiotomy setting, even in bor-
derline situations or after stented biologic
aortic valve prosthesis implantation, can
provide a greater chance of survival in a
poor-prognosis population. Careful clini-
cal, hemodynamic, and residual cardiac
function evaluation can allow surgeons
to stratify patients for prolonged IABP-
inotropic support or timely Impella implan-
tation or even to receive a conventional left
ventricular assist device if cardiac perfor-
mance is dismal.
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Off-pump pulmonary valve
implantation
To the Editor:
We would like to comment on the article
by Berdat and Carrel1 entitled “Off-pump
pulmonary valve replacement with the
new Shelhigh Injectable Stented Pulmonic
Valve.” They are to be congratulated for
having embarked on a novel approach.
Because we have also reported recently
on our first surgical experience implanting
the Shelhigh valve, 2 points should be made.2
First, it is misleading to report on a
pulmonary valve “replacement” in this set-
ting. All 4 patients from the mentioned
group had either undergone the transannu-
lar patch procedure during tetralogy of Fal-
lot repair or commissurotomy. Likewise,
we have also gained, to date, experience
with a total of 6 patients (mean follow-up,
7.8 months; range, 2.0-13.5 months). All of
these had previous tetralogy of Fallot re-
pair. Therefore use of the Shelhigh valve in
its current form allows only for valve “im-
plantation” because the stented valve can
only self-expand and the original pulmonary
valve apparatus remains obviously in situ.
Second, we disagree with the judgment
that a reduction plasty for an enlarged main
pulmonary trunk of larger than 28 mm is
mandatory to ensure an adequate position
of the stented valve. Berdat and Carrel1
made this statement on their experience
with 1 patient only. In our experience with
6 patients (valve sizes, 23-31 mm), periop-
erative assessment included the whole right
ventricular outflow tract, dimensions of the
right ventricle to pulmonary trunk junction,
sinus of Valsalva, pulmonary trunk, and
pulmonary bifurcation. Interestingly, the fi-
nal position of the stented valve was, in our
experience, at different sites: at the level of
the pulmonary valve, just above it, and
even much more distally just in front of the
bifurcation. Therefore we would rather em-
phasize the need for both transesophageal
and epicardial echocardiographic naviga-
tion and “oversizing” of at least 2 mm to
allow for a perfect fit of this new valve
along its struts.
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Reply to the Editor:
We appreciate the comments by Schre-
iber and Lange. We believe that making a
difference between “implantation” and
Letters to the Editor
990 The Journal of Thoracic and Cardiovascular Surgery ● October 2006
“replacement” in this context is rather a
semantic one. In our series of 4 patients,
with 3 having had a transannular patch at
tetralogy of Fallot repair and one having
had a commissurotomy at repair of val-
vular pulmonary stenosis, all patients
have had a native, although stenotic, pul-
monary valve. Therefore by implanting a
pulmonary valve prosthesis within the
native valve, this valve and its function
are being replaced. With regard to an
enlarged right ventricular outflow tract
(RVOT), we believe that reduction plasty
is necessary in patients with a diameter of
greater than 28 mm for 2 reasons. First,
the Shelhigh Injectable Valve is available
in a maximal size of 33 mm. Following
the recommendations of Schreiber with
oversizing of at least 2 mm would mean
that patients with an RVOT of greater
than 31 mm could not be treated with this
new technique. However, it is this subset
of patients with chronic pulmonary regurgi-
tation that present typically with enlarged
RVOT and profit the most from this
method. Second, it is well known from the
literature that an enlarged RVOT is delete-
rious for the function of the right ventricle1
and might be a source for ventricular ar-
rhythmias and consecutive sudden death.2,3
Surgical treatment should therefore not
only be focused on pulmonary valve re-
placement, but also additional problems
should be addressed concomitantly. Be-
cause reduction plasty can also be done
safely and easily off pump, does not lead to
stenosis, and reshapes a conical RVOT to a
more tubular form in which the inserted
valve prosthesis finds better seating, we
would still recommend it. We of course
also perform an in-depth analysis of right
ventricular function and the morphology of
the RVOT by means of transesophageal
and transthoracic echocardiography and
magnetic resonance imaging preopera-
tively to assess the feasibility of this pro-
cedure in an individual patient.
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Tracheal stents in patients with
malignancy
To the Editor:
We read with interest the article by Sihvo
and colleagues1 titled “Fatal Fistula Be-
tween the Trachea and the Brachiocephalic
Artery: Late Complication of a Second-
Generation, Self-Expanding Metallic Tra-
cheal Stent.”
In recent years, the use of this new type
of stent has become more frequent, with a
consequent improvement of quality of life
and survival in patients affected by inoper-
able malignant disease or benign disor-
ders. The use of these stents has been en-
couraged by their easy deployment, which
often can be performed through a fiberoptic
bronchoscope. However, they are expen-
sive, and sometimes their use can be ques-
tioned in patients with a relatively limited
life expectancy and tendency to neoplastic
tissue growth. The second-generation self-
expanding metallic stents reach the largest
diameter in 36 to 48 hours after deploy-
ment. Covered stents should be preferred,
especially in the case of malignancy, to
avoid tissue grow within the mesh of the
stent and formation of granulations.
Traditionally, we have preferred sili-
cone stents (Dumon stents; Novatech, La
Ciotat Cedex, France), having placed more
than 200 of them over a period of 13 years.
Erosion was never a complication. Minor
complications were secretion retention and
granulations on one edge of the stent (1%
in the neoplastic population); also, dis-
placement never happened in patients with
cancer. We also have a small experience
with self-expandable stents (12 patients
with 14 stents); however, they were used in
a very well selected group of patients with
difficult anatomic situations, and most of
them had a tortuous posttransplant bron-
chial stenosis with a malacic component.
In the text of the article it is not clear
whether the first two stents, and in partic-
ular the first one used in that patient, were
covered or not. Could the authors clarify
this?
Again, we encourage the use of silicone
stents in patients with malignant tumors;
they are less expensive, easy to place, and
can be removed or changed if required by
the clinical situation.
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Reply to the Editor:
We thank Drs Anile, Giacomo, and Venuta
for their valuable comments, encouraging
the use of silicone stents in patients with
malignant disease. They state that silicone
stents are less expensive, easy to place, and
can be removed or changed if required by
the clinical situation.
If possible, surgery is the preferred treat-
ment for benign and malignant tracheal
obstruction. However, many patients have
inoperable tumors and must undergo palli-
ation, for example, with stenting, either ex-
pandable metallic stents or silicone stents.
Lately, we have used second-generation me-
tallic stents placed with the aid of a flexible
endoscope because patients with silicone
stents seem to have severe secretion prob-
lems and migration. These complications
lead to stent obstruction necessitating rein-
terventions with a rigid bronchoscope, in-
creasing the total costs of the initially lower
cost treatment. We know the disadvantages
of second-generation self-expanding stents
(tumor ingrowth, especially in uncovered
stents, and difficult removal).1 However,
the quality of the short life after placement
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